Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Wednesday.
Several other analysts have also recently commented on FOLD. JPMorgan Chase & Co. lifted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.88.
Read Our Latest Stock Report on FOLD
Amicus Therapeutics Price Performance
FOLD stock traded up $0.13 during trading on Wednesday, hitting $9.77. The stock had a trading volume of 1,944,625 shares, compared to its average volume of 2,020,068. The company's 50 day moving average price is $9.60 and its two-hundred day moving average price is $10.43. Amicus Therapeutics has a 1-year low of $8.78 and a 1-year high of $14.03. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -28.74, a price-to-earnings-growth ratio of 1.69 and a beta of 0.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.
Insider Transactions at Amicus Therapeutics
In other news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.20% of the company's stock.
Institutional Trading of Amicus Therapeutics
Institutional investors have recently modified their holdings of the company. OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. boosted its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Finally, Covestor Ltd boosted its holdings in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the period.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
